Edison Scientific, Inc

Target selection is one of the earliest and most consequential decisions in drug discovery. Today, we’re introducing Kosmos Target Assessment (TA), a specialized version of Kosmos designed to identify therapeutic candidates with the greatest potential to become the next generation of medicines.

Developed in collaboration with @Incyte, Kosmos TA connects evidence across safety, tractability, competitive intelligence, strategic timing, and more to standardize target evaluation and close the gaps where avoidable attrition takes root.

The results:

  • 𝗪𝗶𝗱𝗲𝗿 𝗹𝗲𝗻𝘀: Kosmos TA delivered its biggest gains in areas outside the core biological rationale, including strategic considerations and portfolio fit

  • 𝗦𝗽𝗲𝗲𝗱: On average, Kosmos TA assessed a target across all categories in less than one workday, granting scientists more time for creative thinking

  • 𝗦𝘁𝗿𝗲𝗮𝗺𝗹𝗶𝗻𝗲𝗱 𝗱𝗲-𝗿𝗶𝘀𝗸𝗶𝗻𝗴: Kosmos TA aligned with committee requested experiments in 83% of cases, enabling researchers to effectively anticipate follow-up studies to streamline de-risking

Small molecule drugs account for more than half of all FDA-approved medicines.

To substantially expedite the advancement of small molecule drugs, today, in collaboration with @ZhongingAlong at @Princeton, we are introducing ChefNMR2, a novel AI system for rapid, automated de novo structure elucidation from simple 1D NMR spectra.

Across five diverse benchmarks comprising 2,031 molecules, ChefNMR2 ranked the correct structure first in 82.4% of cases, compared with 51.9% for standalone Claude Opus 5.

ChefNMR2 is now available in Kosmos for our partners to accelerate small molecule drug discovery.

At Edison, our goal is to bring superintelligence to medicine.

Today, we’re thrilled to announce an agreement with @pfizer to deploy our AI scientist, Kosmos, across Pfizer’s R&D pipeline.

By learning from Pfizer’s robust repositories of data across oncology, immunology, internal medicine and more, Kosmos will enable every program, experiment and clinical readout to sharpen Pfizer’s R&D decision-making and accelerate their pipeline, with compounding advantages to the discovery and development of life-saving medicines.

Last month, alongside @multiplylabs , we hosted an AI x Biotech Block Party, bringing together scientists, founders, pharma partners, and investors for a night of conversation, demos, food, and drinks. Thanks to everyone who joined us!

Our CTO, @andrewwhite01, sat down with Multiply Labs CEO @FredParietti for a fireside chat moderated by @dr_alphalyrae . They explored the role of AI across drug discovery, development, and manufacturing and what it could mean for the future of biotech.

The conversations continued well beyond the fireside chat, and we’re excited to keep them going. If you couldn’t make it this time, there will be more to come.

Writing an Investigational New Drug (IND) application is a major hurdle for drug developers. It can take a team of specialists three to four months, and mistakes can trigger protocol amendments or clinical holds.

In June, we started working with Population Health Partners (PHP) to leverage specialized Kosmos Clinical Protocol Design (“CPD”) and Kosmos Regulatory Authoring (“RA”) products to support PHP’s process of IND preparation.

Since then, specially trained Kosmos products produced a first acceptable draft of the Nonclinical Overview in 4.2 hours, against 100 hours of expert time, flagged an error that roughly fifteen human reviewers missed, and authored 70% of the text in a Pre-IND Briefing Meeting Request submitted to FDA.

PHP is now bringing Kosmos products to a second program and expects to complete IND preparation in as little as 1 month, instead of the 4 month industry standard.

PHP's experts can spend their time reviewing and deciding, not just drafting. The time recovered by Kosmos products means that drugs could make their way to patients faster.